Biliary excretion in dogs: Evidence for a molecular weight threshold

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 1, 2010, Pages 33-37

  Yang, Xinning ^a   Gandhi, Yash A ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Biliary excretion; Dog; Molecular weight; MRP2; ROC curve analysis

Indexed keywords

AMINOPYRIDINE; DANTROLENE; DRUG; IODOXAMIC ACID; NAPSAGATRAN; ANION; CATION; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2;

ANIMAL EXPERIMENT; ANION TRANSPORT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CATION TRANSPORT; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG CLEARANCE; DRUG STRUCTURE; EXPERIMENTAL DOG; MOLECULAR SIZE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; ANIMAL; CHEMISTRY; DOG; FACTUAL DATABASE; HEPATOBILIARY SYSTEM; INTERNET; METABOLISM; PHARMACOKINETICS; SECRETION (PROCESS);

ANIMALS; ANIONS; AREA UNDER CURVE; BILIARY TRACT; CATIONS; DATABASES, FACTUAL; DOGS; INTERNET; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; ROC CURVE;

EID: 77951205006     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.02.005     Document Type: Article

References (24)

1. Abou-El-Makarem M.M., Millburn P., Smith R.L., Williams R.T. Biliary excretion in foreign compounds. Species difference in biliary excretion. Biochem. J. 1967, 105:1289-1293.
2. Bewick V., Cheek L., Ball J. Statistics review 13: receiver operating characteristic curves. Crit. Care 2004, 8:508-512.
3. Chandra P., Brouwer K.L. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 2004, 21:719-735.
4. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1095.
5. Galley H.F. Editorial II: Solid as a ROC. Br. J. Anaesth. 2004, 93:623-626.
6. Hamer D., Sanjeev D., Butterworth E., Barczak P. Using the hospital anxiety and depression scale to screen for psychiatric disorders in people presenting with deliberate self-harm. Br. J. Psychiatry 1991, 158:782-784.
7. Hanley J.A., McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
8. Harter M., Reuter K., Gross-Hardt K., Bengel J. Screening for anxiety, depressive and somatoform disorders in rehabilitation-validity of HADS and GHQ-12 in patients with musculoskeletal disease. Disabil. Rehabil. 2001, 23:737-744.
9. Heredi-Szabo K., Glavinas H., Kis E., Mehn D., Bathori G., Veres Z., Kobori L., von Richter O., Jemnitz K., Krajcsi P. Multidrug resistance protein 2-mediated estradiol-17beta-D-glucuronide transport potentiation: in vitro-in vivo correlation and species specificity. Drug Metab. Dispos. 2009, 37:794-801.
10. Hirom P.C., Millburn P., Smith R.L., Williams R.T. Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem. J. 1972, 129:1071-1077.
11. Hughes R.D., Millburn P., Williams R.T. Biliary excretion of some diquaternary ammonium cations in the rat, guinea pig and rabbit. Biochem. J. 1973, 136:979-984.
12. Hughes R.D., Millburn P., Williams R.T. Molecular weight as a factor in the excretion of monoquaternary ammonium cations in the bile of the rat, rabbit and guinea pig. Biochem. J. 1973, 136:967-978.
13. Ishizuka H., Konno K., Shiina T., Naganuma H., Nishimura K., Ito K., Suzuki H., Sugiyama Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther. 1999, 290:1324-1330.
14. Kato Y., Takahara S., Kato S., Kubo Y., Sai Y., Tamai I., Yabuuchi H., Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab. Dispos. 2008, 36:1088-1096.
15. Mahmood I. Interspecies scaling of biliary excreted drugs: a comparison of several methods. J. Pharm. Sci. 2005, 94:883-892.
16. Millburn P. Factors in the biliary excretion of organic compounds. Metabolic Conjugation and Metabolic Hydrolysis 1970, 1-74. Academic, New York. W. Fishmen (Ed.).
17. Morris M.E., Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 2006, 78:2116-2130.
18. Ninomiya M., Ito K., Horie T. Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab. Dispos. 2005, 33:225-232.
19. Obach R.S., Lombardo F., Waters N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 2008, 36:1385-1405.
20. Roberts M.S., Magnusson B.M., Burczynski F.J., Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 2002, 41:751-790.
21. Sasaki M., Suzuki H., Aoki J., Ito K., Meier P.J., Sugiyama Y. Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol. 2004, 66:450-459.
22. Smith R.L. The Excretory Function of Bile 1973, Chapman & Hall, London, pp. 16-34.
23. Yang X., Gandhi Y.A., Duignan D.B., Morris M.E. Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J. 2009, 11:511-533.
24. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.